Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
December 2, 2002
- Kissei: NHI Price Cut, Sluggish Sales Hit Sales, Profits
December 2, 2002
- Nippon Shinyaku's Cylocide Gets New Indication for Malignant Lymphoma
December 2, 2002
- World Self-Medication Industry 14th General Assembly & 5th Asia Pacific Regional Conference
December 2, 2002
- WEBSITE NEWS
November 25, 2002
- Tanabe Seiyaku: Record Profits Despite Lower Sales
November 25, 2002
- BUSINESS NEWS IN BRIEF
November 25, 2002
- Chugai: Net Loss Due to Merger-related Costs
November 25, 2002
- Abbott Japan to Be Formed on Feb. 2003
November 25, 2002
- Daiichi: Sales, Profits Down from Price Cut Impact on Mainstays
November 25, 2002
- Nippon Kayaku to Make Full Use of Own Unique Technology
November 25, 2002
- Shionogi: Contracting Market Hurts Semiannual Sales, Profits
November 25, 2002
- Eisai Transfers Animal Health Products to Meiji Seika
November 25, 2002
- Sankyo: Sales, Profits Up Due to Export of Mevalotin, Overseas Sales
November 25, 2002
- Ube to Expand Production of Drug Intermediates, Bulk Chemicals
November 25, 2002
- 10 of 14 Top Drugmakers Report Increase in Sales in 1st Half
November 25, 2002
- Priority Order Proposed for Science, Technology-related Budgets
November 25, 2002
- Amino Acids to Remain Core of Ajinomoto's Pharma Business
November 25, 2002
- Meet the Leaders (11)
November 25, 2002
- REGULATORY NEWS IN BRIEF
November 25, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…